You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.

This drug entry is a stub and has not been fully annotated. It was added on October 29, 2015 and is scheduled to be annotated soon.

NameMagnesium Trisilicate
Accession NumberDB09281
TypeSmall Molecule
GroupsApproved
Description

Magnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers. It increases the pH of gastric juice via a neutralisation reaction. It also precipitates colloidal silica, which can coat gastrointestinal mucosa conferring further protection.

IndicationFor the treatment of peptic ulcers.
Structure
Thumb
SynonymsNot Available
ProductsNot Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Alka Phenyl TabDuchesnay Inc.
Alka Phenylbutazone TabPro Doc Limitee
Gasulsol TabHerbes Universelles Inc.
GasvaLes Produits Gerbex Inc.
Gaviscon Regular StrengthGlaxo Smith Kline Consumer Heathcare Lp
Mag-A-folic TabMetagenics, Inc.
Phenylone Plus TabMedic Laboratory Lt√Če
R90 Anti-acide TabDr Reckeweg Canada
Spasmo Nil TabDuchesnay Inc.
Salts
Name/CASStructureProperties
Magnesium trisilicate hydrate
39365-87-2
Thumb
  • InChI Key: FSBVERYRVPGNGG-UHFFFAOYSA-N
  • Monoisotopic Mass: 277.87074465
  • Average Mass: 278.872
DBSALT001821
CAS number14987-04-3
WeightAverage: 260.857
Monoisotopic: 259.86017997
Chemical FormulaMg2O8Si3
InChI KeyGXGAKHNRMVGRPK-UHFFFAOYSA-N
InChI
InChI=1S/2Mg.O8Si3/c;;1-9(2)7-11(5,6)8-10(3)4/q2*+2;-4
IUPAC Name
dimagnesium(2+) ion {[dioxido({[oxido(oxo)silyl]oxy})silyl]oxy}silanoylolate
SMILES
[Mg++].[Mg++].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O
Drug Interactions
Drug
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Magnesium Trisilicate.
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Magnesium Trisilicate.
2,5-Dimethoxy-4-ethylamphetamineMagnesium Trisilicate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.
3,4-MethylenedioxyamphetamineMagnesium Trisilicate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.
3,4-MethylenedioxymethamphetamineMagnesium Trisilicate may decrease the excretion rate of 3,4-Methylenedioxymethamphetamine which could result in a higher serum level.
4-AndrostenedioneThe bioavailability of 4-Androstenedione can be decreased when combined with Magnesium Trisilicate.
4-Bromo-2,5-dimethoxyamphetamineMagnesium Trisilicate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Magnesium Trisilicate.
AcepromazineMagnesium Trisilicate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AceprometazineMagnesium Trisilicate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Magnesium Trisilicate.
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Magnesium Trisilicate.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magnesium Trisilicate.
AlimemazineMagnesium Trisilicate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AllopurinolMagnesium Trisilicate can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Magnesium Trisilicate.
AmphetamineMagnesium Trisilicate may decrease the excretion rate of Amphetamine which could result in a higher serum level.
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Magnesium Trisilicate.
AtazanavirMagnesium Trisilicate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Magnesium Trisilicate.
BeclomethasoneThe bioavailability of Beclomethasone can be decreased when combined with Magnesium Trisilicate.
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Magnesium Trisilicate.
BenzphetamineMagnesium Trisilicate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Magnesium Trisilicate.
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium Trisilicate.
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Magnesium Trisilicate.
BL-1020Magnesium Trisilicate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Magnesium Trisilicate.
BudesonideThe bioavailability of Budesonide can be decreased when combined with Magnesium Trisilicate.
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Magnesium Trisilicate.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Magnesium Trisilicate.
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium Trisilicate.
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Magnesium Trisilicate.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Magnesium Trisilicate.
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Magnesium Trisilicate.
ChlorphentermineMagnesium Trisilicate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.
ChlorpromazineMagnesium Trisilicate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ChlortetracyclineMagnesium Trisilicate can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Magnesium Trisilicate.
CinoxacinMagnesium Trisilicate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiprofloxacinMagnesium Trisilicate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Magnesium Trisilicate.
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Magnesium Trisilicate.
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Magnesium Trisilicate.
ClodronateThe serum concentration of Clodronate can be decreased when it is combined with Magnesium Trisilicate.
Coenzyme Q10The serum concentration of Coenzyme Q10 can be decreased when it is combined with Magnesium Trisilicate.
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Magnesium Trisilicate.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium Trisilicate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium Trisilicate.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Magnesium Trisilicate.
DasatinibMagnesium Trisilicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Magnesium Trisilicate.
dehydroepiandrosterone sulfateThe bioavailability of dehydroepiandrosterone sulfate can be decreased when combined with Magnesium Trisilicate.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Magnesium Trisilicate.
DemeclocyclineMagnesium Trisilicate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Magnesium Trisilicate.
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Magnesium Trisilicate.
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Magnesium Trisilicate.
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Magnesium Trisilicate.
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Magnesium Trisilicate.
DexmethylphenidateMagnesium Trisilicate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DextroamphetamineMagnesium Trisilicate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.
DiethylpropionMagnesium Trisilicate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Magnesium Trisilicate.
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Magnesium Trisilicate.
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Magnesium Trisilicate.
Dipotassium phosphateMagnesium Trisilicate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
DoxycyclineMagnesium Trisilicate can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Magnesium Trisilicate.
EnoxacinMagnesium Trisilicate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
EquileninThe bioavailability of Equilenin can be decreased when combined with Magnesium Trisilicate.
EquilinThe bioavailability of Equilin can be decreased when combined with Magnesium Trisilicate.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Magnesium Trisilicate.
EstroneThe bioavailability of Estrone can be decreased when combined with Magnesium Trisilicate.
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Magnesium Trisilicate.
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium Trisilicate.
Ferric CarboxymaltoseMagnesium Trisilicate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric CitrateMagnesium Trisilicate can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ferric pyrophosphateMagnesium Trisilicate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Magnesium Trisilicate.
FleroxacinMagnesium Trisilicate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
fluasteroneThe bioavailability of fluasterone can be decreased when combined with Magnesium Trisilicate.
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium Trisilicate.
FlumequineMagnesium Trisilicate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Magnesium Trisilicate.
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Magnesium Trisilicate.
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Magnesium Trisilicate.
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Magnesium Trisilicate.
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Magnesium Trisilicate.
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Magnesium Trisilicate.
FluphenazineMagnesium Trisilicate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Magnesium Trisilicate.
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Magnesium Trisilicate.
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Magnesium Trisilicate.
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Magnesium Trisilicate.
Fluticasone PropionateThe bioavailability of Fluticasone Propionate can be decreased when combined with Magnesium Trisilicate.
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Magnesium Trisilicate.
FormestaneThe bioavailability of Formestane can be decreased when combined with Magnesium Trisilicate.
FosinoprilThe serum concentration of Fosinopril can be decreased when it is combined with Magnesium Trisilicate.
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Magnesium Trisilicate.
GarenoxacinMagnesium Trisilicate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
GatifloxacinMagnesium Trisilicate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Magnesium Trisilicate.
GemifloxacinMagnesium Trisilicate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
GrepafloxacinMagnesium Trisilicate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
HE3286The bioavailability of HE3286 can be decreased when combined with Magnesium Trisilicate.
HexamethylenetetramineThe therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Magnesium Trisilicate.
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Magnesium Trisilicate.
HydroxyamfetamineMagnesium Trisilicate may decrease the excretion rate of Hydroxyamphetamine hydrobromide which could result in a higher serum level.
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium Trisilicate.
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Magnesium Trisilicate.
IronMagnesium Trisilicate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron DextranMagnesium Trisilicate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
Iron saccharateMagnesium Trisilicate can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.
IsoniazidMagnesium Trisilicate can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Magnesium Trisilicate.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium Trisilicate.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Magnesium Trisilicate.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Magnesium Trisilicate.
LevofloxacinMagnesium Trisilicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
LisdexamfetamineMagnesium Trisilicate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.
LomefloxacinMagnesium Trisilicate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Magnesium Trisilicate.
ME-609The bioavailability of ME-609 can be decreased when combined with Magnesium Trisilicate.
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Magnesium Trisilicate.
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Magnesium Trisilicate.
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Magnesium Trisilicate.
MemantineThe serum concentration of Memantine can be increased when it is combined with Magnesium Trisilicate.
MephedroneMagnesium Trisilicate may decrease the excretion rate of Mephedrone which could result in a higher serum level.
MephentermineMagnesium Trisilicate may decrease the excretion rate of Mephentermine which could result in a higher serum level.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium Trisilicate.
MesoridazineMagnesium Trisilicate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MethamphetamineMagnesium Trisilicate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.
MethotrimeprazineMagnesium Trisilicate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylene blueMagnesium Trisilicate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.
MethylphenidateMagnesium Trisilicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Magnesium Trisilicate.
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Magnesium Trisilicate.
MinocyclineMagnesium Trisilicate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
MisoprostolThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Misoprostol.
MMDAMagnesium Trisilicate may decrease the excretion rate of MMDA which could result in a higher serum level.
MometasoneThe bioavailability of Mometasone can be decreased when combined with Magnesium Trisilicate.
MoricizineMagnesium Trisilicate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MoxifloxacinMagnesium Trisilicate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolic acidMagnesium Trisilicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Nalidixic AcidMagnesium Trisilicate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Magnesium Trisilicate.
NemonoxacinMagnesium Trisilicate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium Trisilicate.
NitrofurantoinThe serum concentration of Nitrofurantoin can be decreased when it is combined with Magnesium Trisilicate.
NorfloxacinMagnesium Trisilicate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
OfloxacinMagnesium Trisilicate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oleoyl estroneThe bioavailability of Oleoyl estrone can be decreased when combined with Magnesium Trisilicate.
OxytetracyclineMagnesium Trisilicate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Magnesium Trisilicate.
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Magnesium Trisilicate.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium Trisilicate.
PazufloxacinMagnesium Trisilicate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
PefloxacinMagnesium Trisilicate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Magnesium Trisilicate.
PerazineMagnesium Trisilicate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PerphenazineMagnesium Trisilicate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PhentermineMagnesium Trisilicate may decrease the excretion rate of Phentermine which could result in a higher serum level.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Magnesium Trisilicate.
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Polystyrene sulfonate.
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Magnesium Trisilicate.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Magnesium Trisilicate.
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium Trisilicate.
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Magnesium Trisilicate.
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Magnesium Trisilicate.
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Magnesium Trisilicate.
ProchlorperazineMagnesium Trisilicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PromazineMagnesium Trisilicate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PromethazineMagnesium Trisilicate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PropiopromazineMagnesium Trisilicate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
PrulifloxacinMagnesium Trisilicate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
PseudoephedrineMagnesium Trisilicate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.
QuinidineMagnesium Trisilicate may decrease the excretion rate of Quinidine which could result in a higher serum level.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Magnesium Trisilicate.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Magnesium Trisilicate.
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Magnesium Trisilicate.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Magnesium Trisilicate.
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Trisilicate.
RitobegronMagnesium Trisilicate may decrease the excretion rate of Ritobegron which could result in a higher serum level.
RosoxacinMagnesium Trisilicate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium Trisilicate.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Magnesium Trisilicate.
Sodium glycerophosphateMagnesium Trisilicate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium phosphatesMagnesium Trisilicate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Magnesium Trisilicate.
SparfloxacinMagnesium Trisilicate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Magnesium Trisilicate.
Technetium tc 99m etidronateThe serum concentration of Technetium tc 99m etidronate can be decreased when it is combined with Magnesium Trisilicate.
Technetium Tc-99m MedronateThe serum concentration of Technetium Tc-99m Medronate can be decreased when it is combined with Magnesium Trisilicate.
TemafloxacinMagnesium Trisilicate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
TetracyclineMagnesium Trisilicate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
ThiethylperazineMagnesium Trisilicate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
ThioridazineMagnesium Trisilicate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
TiludronateThe serum concentration of Tiludronate can be decreased when it is combined with Magnesium Trisilicate.
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Magnesium Trisilicate.
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Magnesium Trisilicate.
TriethylenetetramineMagnesium Trisilicate can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.
TrifluoperazineMagnesium Trisilicate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
TriflupromazineMagnesium Trisilicate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
TrovafloxacinMagnesium Trisilicate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium Trisilicate.
External Links
ReferencesNot Available
Comments
comments powered by Disqus
Drug created on October 29, 2015 09:58 / Updated on August 17, 2016 12:24